DK2441767T3 - Salinosporamider og fremgangsmåder til anvendelse deraf - Google Patents

Salinosporamider og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK2441767T3
DK2441767T3 DK11163737.7T DK11163737T DK2441767T3 DK 2441767 T3 DK2441767 T3 DK 2441767T3 DK 11163737 T DK11163737 T DK 11163737T DK 2441767 T3 DK2441767 T3 DK 2441767T3
Authority
DK
Denmark
Prior art keywords
neoplasm
pharmaceutical composition
substituted
compound
agents
Prior art date
Application number
DK11163737.7T
Other languages
English (en)
Inventor
William H Fenical
Paul R Jensen
Tracy J Mincer
Robert H R Feling
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/600,854 external-priority patent/US7179834B2/en
Priority claimed from US10/838,157 external-priority patent/US7176232B2/en
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK2441767T3 publication Critical patent/DK2441767T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (6)

1. Farmaceutisk sammensætning omfattende en effektiv mængde af en farmaceutisk acceptabel bærer og en effektiv mængde af en forbindelse med strukturen af forbindelsen (V):
hvori den farmaceutiske sammensætning yderligere omfatter sukrose.
2. Farmaceutisk sammensætning ifølge krav 1, hvori den farmaceutiske sammensætning er i form af en injicérbar steril opløsning eller et fast stof.
3. Farmaceutisk sammensætning ifølge krav 2, hvori den injicérbare sterile opløsning er en vandig injicérbar steril opløsning.
4. Farmaceutisk sammensætning ifølge ethvert af krav 1 til 3, hvori den farmaceutiske sammensætning yderligere omfatter et yderligere middel.
5. Farmaceutisk sammensætning ifølge ethvert af krav 1 til 4 til anvendelse ved behandling af en proliferativ pattedyrscellelidelse, hvori lidelsen er valgt fra gruppen bestående af bugspytkirteladenokarcinom, centralnervesystemneoplasma, sarkom af blødt væv, sarkom af knogle, hovedneoplasma, halsneoplasma, gastrisk neoplasma, skjoldbruskkirtelneoplasma, maveneoplasma, myelom, blære-neoplasma, neuroendokrin neoplasma, non-Flodgkins sygdom neoplasma og Flod-gkins sygdom neoplasma.
6. Farmaceutisk sammensætning til anvendelse ifølge krav 5, hvori pattedyrscellen er human.
DK11163737.7T 2003-06-20 2004-06-18 Salinosporamider og fremgangsmåder til anvendelse deraf DK2441767T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/600,854 US7179834B2 (en) 2002-06-24 2003-06-20 Salinosporamides and methods for use thereof
US10/838,157 US7176232B2 (en) 2002-06-24 2004-04-30 Salinosporamides and methods for use thereof
EP04776728A EP1638977A4 (en) 2003-06-20 2004-06-18 SALINOSPORAMIDES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
DK2441767T3 true DK2441767T3 (da) 2015-08-24

Family

ID=46713688

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11163737.7T DK2441767T3 (da) 2003-06-20 2004-06-18 Salinosporamider og fremgangsmåder til anvendelse deraf

Country Status (8)

Country Link
KR (1) KR101315595B1 (da)
CY (1) CY1116724T1 (da)
DK (1) DK2441767T3 (da)
ES (1) ES2546415T3 (da)
IL (1) IL240236B (da)
MX (1) MX361003B (da)
PT (1) PT2441767E (da)
SI (1) SI2441767T1 (da)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4322802A (en) 2000-11-16 2002-06-24 Univ California Marine actinomycete taxon for drug and fermentation product dicovery

Also Published As

Publication number Publication date
MX361003B (es) 2018-11-23
IL240236A0 (en) 2015-09-24
SI2441767T1 (sl) 2015-10-30
CY1116724T1 (el) 2017-03-15
ES2546415T3 (es) 2015-09-23
IL240236B (en) 2021-02-28
KR20120081637A (ko) 2012-07-19
PT2441767E (pt) 2015-10-09
KR101315595B1 (ko) 2013-10-08

Similar Documents

Publication Publication Date Title
US10912764B2 (en) Salinosporamides and methods of use thereof
US7179834B2 (en) Salinosporamides and methods for use thereof
EP2441767B1 (en) Salinosporamides and methods for use thereof
DK2441767T3 (da) Salinosporamider og fremgangsmåder til anvendelse deraf
DE69917668T2 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
US7521414B2 (en) Polyol macrolide antitumor-antibiotics from the marine actinomycete strain CNQ140
US6277860B1 (en) Furopyridine antibacterials
KR20050109958A (ko) Ｇｍ-９５ 물질을 함유하는 항종양 효과 증강제, 항종양용조합 제제 및 항종양제
WO2024043829A1 (en) Antimicrobial compounds, methods of production and uses thereof
KR100225458B1 (ko) 믹소코크스 속의 점액세균, 이로부터 생산되는 신규 항종양활성 화합물 및 그의 제조방법
KR20160146414A (ko) 아미드계 유도체 화합물, 이의 생산 방법 및 용도
EP0999212B1 (en) Furopyridine antibacterials